Report Highlights

Diabetes Devices in the United States: Market Overview

The U.S. diabetes devices market was valued at USD 19.6 billion in 2024, spanning continuous glucose monitors, insulin pumps, automated insulin delivery systems, blood glucose meters and insulin delivery devices. The CDC's National Diabetes Statistics Report counts more than 38 million Americans with diabetes, and type 2 diabetes accounts for the large majority of cases. Market structure is concentrated: a handful of manufacturers hold most CGM and pump revenue, while distribution splits between Medicare-contracted suppliers, retail pharmacies and direct-to-consumer channels.

Policy has shaped this market in two distinct ways. Government is the dominant force on payment: Medicare Part B covers insulin pumps and CGMs as durable medical equipment, and the Inflation Reduction Act's USD 35 monthly insulin cap has reset patient cost sharing since 2023. The private sector leads on technology, with Abbott's FreeStyle Libre and Dexcom's G7 driving sensor innovation, while Insulet and Tandem push integrated automated insulin delivery.

Policy-Driven Growth in US Diabetes Devices

Three federal mechanisms are driving demand. First, CMS expanded Medicare coverage for CGMs through Local Coverage Determination L33822 for Glucose Monitors, administered by the DME Medicare Administrative Contractors, which extended eligibility from multiple daily insulin injections to all insulin users and patients with documented problematic hypoglycemia. Coverage translates into volume: each newly eligible beneficiary generates recurring sensor and supply revenue under the Part B durable medical equipment benefit.

Second, Section 11406 of the Inflation Reduction Act of 2022 (Public Law 117-169) capped Part D insulin copayments at USD 35 per month from January 1, 2023, lowering the cost barrier to insulin therapy that pumps and CGMs supplement. Third, the FDA's integrated CGM special controls under 21 CFR 862.1355, together with the 2024 over-the-counter clearances for Dexcom Stelo and Abbott Lingo, extend demand to adults who do not use insulin, converting a prescription-only category into a cash-pay consumer market.

Regulatory Barriers and Compliance Costs

FDA premarket review under the Federal Food, Drug, and Cosmetic Act controls market entry. Automated insulin delivery systems require premarket approval (PMA) through the Center for Devices and Radiological Health, with an MDUFA performance goal of 180 review days excluding clock stops. Original PMA applications carry user fees above USD 500,000, while Section 524B of the Act, effective March 2023, requires cybersecurity plans, software bills of materials and vulnerability management for connected pumps and sensors.

Medicare supplier standards add a second barrier. Under 42 CFR 424.57, DMEPOS suppliers must hold accreditation from a CMS-approved organization, maintain state licensure where applicable and post a USD 50,000 surety bond, costs that small retailers often cannot absorb. Competitive bidding under Section 1847 of the Social Security Act sets contract rates that CMS administers, compressing supplier margins where bids are awarded below prevailing fee schedules.

Policy-Created Opportunities for Diabetes Devices in the United States

The next Medicare DMEPOS competitive bidding round, which includes continuous glucose monitors and insulin pumps, creates a contract-based opportunity for suppliers able to meet remote item delivery requirements. CMS adopted the remote item delivery program in its CY 2024 final rule, allowing winning suppliers to ship sensors and supplies to beneficiaries nationwide without local storage. This model favors national distributors with centralized fulfillment networks.

Over-the-counter continuous glucose monitoring creates a cash-pay segment outside Medicare. Dexcom Stelo, cleared by the FDA in 2024 for adults not using insulin, sells directly to consumers, and retailers that stock OTC sensors capture share from prescription-only channels. Manufacturers with iCGM clearance and pharmacy partnerships can expand into prediabetes and type 2 populations without awaiting payer decisions.

Market at a Glance

Leading Market Participants

• Abbott
• Dexcom
• Medtronic
• Insulet
• Tandem Diabetes Care
• Roche Diagnostics
• LifeScan
• Ascensia Diabetes Care
• Senseonics
• Embecta

Regulatory and Policy Environment

The primary legislation is the Federal Food, Drug, and Cosmetic Act, administered by the FDA's Center for Devices and Radiological Health and amended by the Medical Device User Fee Amendments, reauthorized for fiscal years 2023 to 2027. Reimbursement is governed by Title XVIII of the Social Security Act and the Inflation Reduction Act of 2022, implemented by CMS through DME Medicare Administrative Contractors. Key compliance requirements include 21 CFR Part 807 device registration, the 21 CFR Part 820 quality system regulation and Section 524B cybersecurity obligations.

Upcoming changes include the Quality Management System Regulation taking effect February 2, 2026, MDUFA VI negotiations ahead of reauthorization by September 30, 2027, and Medicare competitive bidding contracts scheduled for 2028. Against regional peers, the U.S. framework differs from Canada's Medical Devices Regulations (SOR/98-282), which pair a risk-based licence model with provincial reimbursement, and the EU Medical Device Regulation (EU) 2017/745, which requires notified-body assessment. The FDA's 510(k) and De Novo pathways are faster than the EU route, but Medicare supplier accreditation adds a compliance layer absent in most peer markets.

Long-Term Policy Outlook for Diabetes Devices in the United States

By 2032, MDUFA VI will reset FDA review performance goals and user fee structures, which determine how quickly new automated insulin delivery and sensor platforms reach patients. The FDA will continue expanding over-the-counter pathways for integrated CGMs, shifting volume from prescription channels toward retail and digital health platforms governed by cybersecurity and software-as-a-medical-device guidance.

Medicare competitive bidding will be the single largest reshaping force, as contracts effective in 2028 consolidate CGM and pump supply into fewer national suppliers. Sensor price pressure will push manufacturers toward subscription and pharmacy-benefit models, while Medtronic's separation of its diabetes business as MiniMed will test whether specialized insulin-pump companies can sustain independent reimbursement negotiations.